May 14, 2026
Baricitinib for Vitiligo: Phase 3 Data and What to Expect
Baricitinib is an oral JAK1/2 inhibitor approved for alopecia areata and rheumatoid arthritis with emerging Phase 3 data for vitiligo. Here is what the trial evidence shows and how it compares to other JAK inhibitors.